

Measure 109

Campaign Debrief & Next Steps for Psilocybin Therapy in Oregon and Beyond

Oregonians Are Suffering Now, More Than ever

- 1. According to a recent survey conducted by CDC's National Center for Health Statistics and the Census Bureau: At the start of quarantine, 1 in 5 Americans were experiencing symptoms of clinical anxiety or depression, but now over a third of Americans say they are experiencing symptoms amid the country's new coronavirus epidemic.
- 2. Here in Oregon, the mental health crisis is even more acute. According to Mental Health America, **Oregon's mental health crisis is the most severe in the country, and that was before the pandemic hit.**

Psilocybin Research

- Rigorous studies at the leading medical research institutions such as Johns Hopkins, UCLA, and NYU show that psilocybin works. It is uniquely effective in treating depression, end-of-life anxiety, and addiction.
- It shows so much promise the FDA recently granted it a "breakthrough therapy" designation - meaning that it may demonstrate substantial improvement above and beyond what is currently available.







Department of Psychiatry






































The Measure



M 109: A measured approach

GOAL: Create licensing and regulatory framework to serve those who seek Psilocybin Therapy and could safely benefit from it.

What Measure 109 Does

- Establishes a <u>regulatory framework</u> within the Oregon Health Authority (OHA) that will allow trained practitioners to administer psilocybin services at specially licensed centers
- Establishes the Oregon Psilocybin Advisory Board, appointed by the Governor
- Imposes a **two-year development period** before initial licenses are granted
- Requires the establishment of a <u>training and licensure</u> system for psilocybin facilitators, psilocybin manufacturers, and testing labs
- Requires the establishment of a <u>tracking system</u> for psilocybin products

M 109 does NOT allow:

- Retail sales
- Off-site consumption or possession
- Branding or advertising
- Unregulated or untracked psilocybin production, delivery, or inventory
- Therapy centers in residential neighborhoods or near a school
- Access for minors

Psilocybin services modality

1. Preparation session

- Informed consent with health and safety warning
- Standardized risk assessment, contraindication screening required
- Mental health review, goodness of fit assessment

1. Psilocybin session

- Must occur at a psilocybin service center
- Facilitator present throughout entire process
- Facilitator must certify completion

1. Integration session

Must be offered by facilitator after completion of administration session

Measure 109 By The Numbers

Measure 109 Vote Summary

- 56% of Oregon voters YES to Measure 109
- The following 15 counties voted in favor of Measure 109
 - Benton
 - Clackamas
 - Clatsop
 - Columbia
 - Curry
 - Deschutes
 - Hood River
 - Jackson

- Lane
- Lincoln
- Multnomah
- Tillamook
- Wasco
- Washington
- Yamhill

Implementation

Overview

- Measure 109 establishes an initial <u>two-year development period</u>.
- During that period, the Oregon Health Authority, <u>with the guidance of an Advisory Board</u>, will study psilocybin research and science and develop a regulatory program, including <u>rules, training</u> <u>requirements</u>, and <u>licensing requirements</u>.
- In January 2023, at the completion of the two-year study period, OHA will begin accepting applications and issuing licenses to:
 - manufacture psilocybin products,
 - o operate psilocybin service centers, and
 - <u>facilitate</u> psilocybin therapy services.


Advisory Board Details

The Advisory Board is appointed by the Governor, with detailed requirements. The Governor must appoint:

- Any four of the following:
 - A state employee with technical expertise in public health
 - A local health officer.
 - o A member of a federally recognized Indian tribe in Oregon
 - A member of the OHA Addictions and Mental Health Planning and Advisory Council
 - o A member of the OHA Health Equity Policy Committee
 - A member of the OHA Palliative Care and Quality of Life Interdisciplinary Advisory Council
 - An individual who provides public health services directly to the public
- A licensed psychologist who has professional experience in the treatment of a mental, emotional, or behavioral condition;
- A licensed physician
- A licensed naturopathic physician
- A public health expert with a background in academia

- Any three of the following:
 - A person with professional experience conducting scientific research regarding the use of psychedelic compounds in clinical therapy
 - A person with experience in the field of mycology
 - A person with experience in the field of ethnobotany
 - A person with experience in the field of psychopharmacology
 - A person with experience in the field of psilocybin harm reduction
- A person representing the Oregon Liquor Control Commission who has experience working with the Oregon system for tracking marijuana
- A person representing the Oregon Department of Justice
- The following:
 - During the two-year program development period:
 - One of the chief petitioners of the initiative
 - One or two at-large members
 - After the two-year program development period, one, two, or three at-large members

Implementation Timeline



Thank You